Two-horse race for TPO

The thrombopoietin picture became a bit clearer last week, as Amgen Inc. and partner Kirin licensed rights to Novo Nordisk's technology covering the platelet booster. That leaves AMGN and Genentech Inc. to square off in the race to get through clinical development, and potentially in a battle over patent rights.